{
    "xml": "<topic id=\"PHP2065\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/methadone-hydrochloride\" basename=\"methadone-hydrochloride\" title=\"METHADONE HYDROCHLORIDE\">\n<title>METHADONE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_97\" namespace=\"/interactions/list-of-drug-interactions/analgesics/opioid-analgesics/methadone\">Methadone</xref>\n</p>\n<data name=\"vtmid\">51758009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_110392128\" title=\"Opioids\">Opioids</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34573\" title=\"OPIOIDS\" namespace=\"/drug-classes/opioids\">OPIOIDS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP69908\" outputclass=\"indicationsAndDose\" rev=\"1.46\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Indications and dose</title>\n<body>\r\n<section outputclass=\"indicationAndDoseGroup\">\r\n<sectiondiv outputclass=\"therapeuticIndications\">\r\n<p outputclass=\"therapeuticIndication\">Severe pain</p>\n</sectiondiv>\r\n<p outputclass=\"routesOfAdministration\">By mouth or by subcutaneous injection or by intramuscular injection</p>\r\n<ul outputclass=\"patientGroups\">\r\n<li outputclass=\"patientGroup adult\">\r\n<p>Adult</p>\r\n<p>5&#8211;10&#8239;mg every 6&#8211;8&#8239;hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours.</p>\n</li>\r\n</ul>\n</section>\r\n<section outputclass=\"indicationAndDoseGroup\">\r\n<sectiondiv outputclass=\"therapeuticIndications\">\r\n<p outputclass=\"therapeuticIndication\">Adjunct in treatment of opioid dependence</p>\n</sectiondiv>\r\n<p outputclass=\"routesOfAdministration\">By mouth using oral solution</p>\r\n<ul outputclass=\"patientGroups\">\r\n<li outputclass=\"patientGroup adult\">\r\n<p>Adult</p>\r\n<p>Initially 10&#8211;30&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>\n</li>\r\n</ul>\n</section>\r\n<section outputclass=\"indicationAndDoseGroup\">\r\n<sectiondiv outputclass=\"therapeuticIndications\">\r\n<p outputclass=\"therapeuticIndication\">Adjunct in treatment of opioid dependence if tolerance low or not known</p>\n</sectiondiv>\r\n<p outputclass=\"routesOfAdministration\">By mouth using oral solution</p>\r\n<ul outputclass=\"patientGroups\">\r\n<li outputclass=\"patientGroup adult\">\r\n<p>Adult</p>\r\n<p>Initially 10&#8211;20&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>\n</li>\r\n</ul>\n</section>\r\n<section outputclass=\"indicationAndDoseGroup\">\r\n<sectiondiv outputclass=\"therapeuticIndications\">\r\n<p outputclass=\"therapeuticIndication\">Adjunct in treatment of opioid dependence if tolerance high (under expert supervision)</p>\n</sectiondiv>\r\n<p outputclass=\"routesOfAdministration\">By mouth using oral solution</p>\r\n<ul outputclass=\"patientGroups\">\r\n<li outputclass=\"patientGroup adult\">\r\n<p>Adult</p>\r\n<p>Initially up to 40&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>\n</li>\r\n</ul>\n</section>\r\n<section outputclass=\"indicationAndDoseGroup\">\r\n<sectiondiv outputclass=\"therapeuticIndications\">\r\n<p outputclass=\"therapeuticIndication\">Cough in terminal disease</p>\n</sectiondiv>\r\n<p outputclass=\"routesOfAdministration\">Initially by mouth using linctus</p>\r\n<ul outputclass=\"patientGroups\">\r\n<li outputclass=\"patientGroup adult\">\r\n<p>Adult</p>\r\n<p>1&#8211;2&#8239;mg every 4&#8211;6&#8239;hours, (by mouth) reduced to 1&#8211;2&#8239;mg twice daily, use twice daily frequency if prolonged use.</p>\n</li>\r\n</ul>\n</section>\r\n\r\n\r\n<section outputclass=\"doseEquivalence\">\r\n<title>Dose equivalence and conversion</title>\r\n<p>See <xref format=\"dita\" href=\"#PHP2680\" type=\"drug\" namespace=\"/drugs/buprenorphine\">buprenorphine</xref> for dose adjustments in opioid substitution therapy, for patients taking methadone who want to switch to buprenorphine.</p>\n</section>\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP69715\" outputclass=\"unlicensedUse\" rev=\"1.18\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69975\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Methadone oral solution 1&#8239;mg/mL is 2&#189; times the strength of Methadone Linctus (2&#8239;mg/5mL). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69983\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70002\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Family history of sudden death (ECG monitoring recommended)</ph>; <ph outputclass=\"caution\">history of cardiac conduction abnormalities</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">QT-interval prolongation</p>\n<p>Patients with the following risk factors for QT-interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100&#8239;mg daily should also be monitored.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69775\" outputclass=\"sideEffects\" rev=\"1.25\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dry eyes</ph>; <ph outputclass=\"sideEffect\">dysmenorrhoea</ph>; <ph outputclass=\"sideEffect\">hyperprolactinaemia</ph>; <ph outputclass=\"sideEffect\">hypothermia</ph>; <ph outputclass=\"sideEffect\">QT-interval prolongation</ph>; <ph outputclass=\"sideEffect\">raised intracranial pressure</ph>; <ph outputclass=\"sideEffect\">restlessness</ph>; <ph outputclass=\"sideEffect\">torsade de pointes</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Methadone is a long-acting opioid therefore effects may be cumulative.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Methadone, even in low doses is a <b>special hazard</b> for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsOverdosageInformation\">\n<title>Overdose</title>\n<sectiondiv>\n<p> Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70010\" outputclass=\"breastFeeding\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Withdrawal symptoms in infant; breast-feeding permissible during maintenance but dose should be as low as possible and infant monitored to avoid sedation (high doses of methadone carry an increased risk of sedation and respiratory depression in the neonate).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69843\" outputclass=\"renalImpairment\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69743\" outputclass=\"treatmentCessation\" rev=\"1.13\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid abrupt withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70030\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57640\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.21\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of oral liquid formulations may include tolu.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69653\" outputclass=\"nationalFunding\" rev=\"1.24\" parent=\"/drugs/methadone-hydrochloride\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA114</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Methadone and buprenorphine for the management of opioid dependence (January 2007)</p>\r\n<p>Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA114\">www.nice.org.uk/TA114</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP69676\" outputclass=\"lessSuitableForPrescribing\" rev=\"1.16\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Less suitable for prescribing</title>\n<body>\n<section>\n<sectiondiv>\n<p>Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2065-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/methadone-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: tablet, suppository, solution for injection, oral suspension, oral solution, capsule, impregnated cigarette</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75584\" title=\"Tablet\" namespace=\"/drugs/methadone-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75577\" title=\"Oral solution\" namespace=\"/drugs/methadone-hydrochloride/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75604\" title=\"Solution for injection\" namespace=\"/drugs/methadone-hydrochloride/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"2\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97239\" namespace=\"/guidance/controlled-drugs-and-drug-dependence\" title=\"Controlled drugs and drug dependence\" count=\"1\" rel=\"backlink\">Controlled drugs and drug dependence</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78300\" namespace=\"/treatment-summaries/aromatic-inhalations-cough-preparations-and-systemic-nasal-decongestants\" title=\"Aromatic inhalations, cough preparations and systemic nasal decongestants\" count=\"2\" rel=\"backlink\">Aromatic inhalations, cough preparations and systemic nasal decongestants</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78520\" namespace=\"/treatment-summaries/analgesics\" title=\"Analgesics\" count=\"3\" rel=\"backlink\">Analgesics</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"20\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_97\" namespace=\"/interactions/list-of-drug-interactions/analgesics/opioid-analgesics/methadone\" title=\"Methadone\" count=\"1\" rel=\"link\">Methadone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34573\" namespace=\"/drug-classes/opioids\" title=\"OPIOIDS\" count=\"1\" rel=\"link\">OPIOIDS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP2680\" namespace=\"/drugs/buprenorphine\" title=\"BUPRENORPHINE\" count=\"1\" rel=\"link\">BUPRENORPHINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75584\" namespace=\"/drugs/methadone-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75577\" namespace=\"/drugs/methadone-hydrochloride/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75604\" namespace=\"/drugs/methadone-hydrochloride/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2065",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/methadone-hydrochloride",
    "basename": "methadone-hydrochloride",
    "title": "METHADONE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_97",
            "label": "Methadone"
        }
    ],
    "vtmid": "51758009",
    "drugClassification": [
        "Opioids"
    ],
    "inheritsFromClass": [
        "OPIOIDS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe pain",
                        "html": "Severe pain"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or subcutaneous injection or intramuscular injection"
                    ],
                    "textContent": "By mouth or by subcutaneous injection or by intramuscular injection",
                    "html": "By mouth or by subcutaneous injection or by intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "5&#8211;10 mg every 6&#8211;8 hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours.",
                        "html": "<p>5&#8211;10&#8239;mg every 6&#8211;8&#8239;hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunct in treatment of opioid dependence",
                        "html": "Adjunct in treatment of opioid dependence"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using oral solution"
                    ],
                    "textContent": "By mouth using oral solution",
                    "html": "By mouth using oral solution"
                },
                "adult": [
                    {
                        "textContent": "Initially 10&#8211;30 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.",
                        "html": "<p>Initially 10&#8211;30&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunct in treatment of opioid dependence if tolerance low or not known",
                        "html": "Adjunct in treatment of opioid dependence if tolerance low or not known"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using oral solution"
                    ],
                    "textContent": "By mouth using oral solution",
                    "html": "By mouth using oral solution"
                },
                "adult": [
                    {
                        "textContent": "Initially 10&#8211;20 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.",
                        "html": "<p>Initially 10&#8211;20&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunct in treatment of opioid dependence if tolerance high (under expert supervision)",
                        "html": "Adjunct in treatment of opioid dependence if tolerance high (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using oral solution"
                    ],
                    "textContent": "By mouth using oral solution",
                    "html": "By mouth using oral solution"
                },
                "adult": [
                    {
                        "textContent": "Initially up to 40 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.",
                        "html": "<p>Initially up to 40&#8239;mg daily, increased in steps of 5&#8211;10&#8239;mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30&#8239;mg; usual dose 60&#8211;120&#8239;mg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Cough in terminal disease",
                        "html": "Cough in terminal disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially mouth using linctus"
                    ],
                    "textContent": "Initially by mouth using linctus",
                    "html": "Initially by mouth using linctus"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 mg every 4&#8211;6 hours, (by mouth) reduced to 1&#8211;2 mg twice daily, use twice daily frequency if prolonged use.",
                        "html": "<p>1&#8211;2&#8239;mg every 4&#8211;6&#8239;hours, (by mouth) reduced to 1&#8211;2&#8239;mg twice daily, use twice daily frequency if prolonged use.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "references": [
                    {
                        "id": "PHP2680",
                        "label": "buprenorphine"
                    }
                ],
                "title": "Dose equivalence and conversion",
                "textContent": "See buprenorphine for dose adjustments in opioid substitution therapy, for patients taking methadone who want to switch to buprenorphine.",
                "html": "<p>See <xref format=\"dita\" href=\"#PHP2680\" type=\"drug\" namespace=\"/drugs/buprenorphine\">buprenorphine</xref> for dose adjustments in opioid substitution therapy, for patients taking methadone who want to switch to buprenorphine.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.",
                "html": "<p>Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Methadone oral solution 1 mg/mL is 2&#189; times the strength of Methadone Linctus (2 mg/5mL). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.",
                "html": "<p>Methadone oral solution 1&#8239;mg/mL is 2&#189; times the strength of Methadone Linctus (2&#8239;mg/5mL). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Phaeochromocytoma",
                "html": "Phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Family history of sudden death (ECG monitoring recommended)",
                "html": "Family history of sudden death (ECG monitoring recommended)"
            },
            {
                "type": "cautions",
                "textContent": "history of cardiac conduction abnormalities",
                "html": "history of cardiac conduction abnormalities"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "QT-interval prolongation",
                "textContent": "Patients with the following risk factors for QT-interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100 mg daily should also be monitored.",
                "html": "<p>Patients with the following risk factors for QT-interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100&#8239;mg daily should also be monitored.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Dry eyes",
                        "html": "Dry eyes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dysmenorrhoea",
                        "html": "dysmenorrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperprolactinaemia",
                        "html": "hyperprolactinaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypothermia",
                        "html": "hypothermia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "raised intracranial pressure",
                        "html": "raised intracranial pressure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "restlessness",
                        "html": "restlessness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "torsade de pointes",
                        "html": "torsade de pointes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Methadone is a long-acting opioid therefore effects may be cumulative.",
                "html": "<p>Methadone is a long-acting opioid therefore effects may be cumulative.</p>"
            },
            {
                "type": "advice",
                "textContent": "Methadone, even in low doses is a special hazard for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.",
                "html": "<p>Methadone, even in low doses is a <b>special hazard</b> for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.</p>"
            }
        ],
        "overdosageInformation": [
            {
                "type": "overdosageInformation",
                "textContent": "Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.",
                "html": "<p> Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Withdrawal symptoms in infant; breast-feeding permissible during maintenance but dose should be as low as possible and infant monitored to avoid sedation (high doses of methadone carry an increased risk of sedation and respiratory depression in the neonate).",
                "html": "<p>Withdrawal symptoms in infant; breast-feeding permissible during maintenance but dose should be as low as possible and infant monitored to avoid sedation (high doses of methadone carry an increased risk of sedation and respiratory depression in the neonate).</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.",
                "html": "<p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Avoid abrupt withdrawal.",
                "html": "<p>Avoid abrupt withdrawal.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.",
                "html": "<p>Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of oral liquid formulations may include tolu.",
                "html": "<p>Flavours of oral liquid formulations may include tolu.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA114",
                        "label": "www.nice.org.uk/TA114"
                    }
                ],
                "fundingIdentifier": "NICE TA114",
                "textContent": "Methadone and buprenorphine for the management of opioid dependence (January 2007) Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.\n\nwww.nice.org.uk/TA114",
                "html": "<p outputclass=\"title\">Methadone and buprenorphine for the management of opioid dependence (January 2007)</p> <p>Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA114\">www.nice.org.uk/TA114</xref>"
            }
        ]
    },
    "lessSuitableForPrescribing": {
        "lessSuitableForPrescribing": [
            {
                "type": "lessSuitableForPrescribing",
                "textContent": "Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).",
                "html": "<p>Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "tablet",
                "suppository",
                "solution for injection",
                "oral suspension",
                "oral solution",
                "capsule",
                "impregnated cigarette"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75584",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75577",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75604",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP97239",
                "label": "Controlled drugs and drug dependence",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78300",
                "label": "Aromatic inhalations, cough preparations and systemic nasal decongestants",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78520",
                "label": "Analgesics",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_97",
                "label": "Methadone",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34573",
                "label": "OPIOIDS",
                "type": "drugClass"
            }
        ],
        "drug": [
            {
                "id": "PHP2680",
                "label": "BUPRENORPHINE",
                "type": "drug"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75584",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75577",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75604",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}